BC Innovations | Nov 6, 2019
Distillery Therapeutics

Peptide inhibitors of a histone chaperone for osteosarcoma and breast cancer

DISEASE CATEGORY: Cancer INDICATION: Bone cancer; breast cancer A team from the French Alternative Energies and Atomic Energy Commission identified two peptide inhibitors of the histone chaperone ASF1A that could treat osteosarcoma and breast cancer....
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Innovations | May 20, 2019
Distillery Therapeutics

HIST4H4 inhibition to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Mouse studies suggest inhibiting HIST4H4 or its interaction with the cell membrane could help treat atherosclerosis. In a mouse model of atherosclerosis, a mAb against HIST4H4 or a cyclical peptide...
BC Extra | Feb 27, 2019
Clinical News

Novartis first partner in RWE collaboration for dermatology

PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program. TARGET-DERM will gather real world, de-identified patient-level data from electronic medical records...
BC Week In Review | Aug 31, 2018
Company News

JW grants Leo rights to atopic dermatitis candidate JW1601

JW Pharmaceutical Corp. (KSE:001060) granted Leo Pharma A/S (Ballerup, Denmark) exclusive rights to develop and commercialize JW1601 worldwide, excluding Korea. This year, JW expects to submit an IND in Korea for a Phase I trial...
BioCentury | Mar 10, 2018
Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
BioCentury | Jul 21, 2017

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BC Week In Review | Dec 30, 2016
Company News

Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist. Ziarco previously said ZPL-389 missed the primary endpoint but significantly reduced Eczema...
BC Extra | Dec 16, 2016
Company News

Novartis gets eczema candidate in Ziarco takeout

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring Ziarco Group Ltd. (Canterbury, U.K.). The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist that has completed a Phase IIa trial to treat...
BC Innovations | Jun 16, 2016
Targets & Mechanisms

Vedanta's horizons

Vedanta Biosciences Inc. has followed up its March double-hit of publishing preclinical proof of concept for its homegrown, microbiome-based therapies and in-licensing a new technology to expand the portfolio, with its closing last week of...
Items per page:
1 - 10 of 34